Document:

EX-10.12

 Exhibit 10.12 
 EVOGENE 2013 SHARE OPTION PLAN 
  

 
 THE 

EVOGENE LTD. 
 2013 SHARE OPTION PLAN 

 EVOGENE 2013 SHARE OPTION PLAN 

 
  
  

 This plan, as amended from time to time, shall be known as the Evogene Ltd. 2013 Share Option Plan (the
“Plan”). 
  

	1.	PURPOSE OF THE PLAN 

 The
Plan is intended to provide an incentive to retain, in the employ of the Company and its Affiliates (as defined below), persons of training, experience, and ability, to attract new employees, directors, consultants, service providers and any other
entity which the Board shall decide their services are considered valuable to the Company, to encourage the sense of proprietorship of such persons, and to stimulate the active interest of such persons in the development and financial success of the
Company by providing them with opportunities to purchase shares in the Company, pursuant to the Plan. 
  

	2.	DEFINITIONS 

 For purposes
of the Plan and related documents, including the Option Letter of Agreement, the following definitions shall apply: 
  

	 	2.1.	“Affiliate” means any entity controlling, controlled by or under common control with, the Company, with respect to which the Company constitutes an
“employing company” within the meaning of Section 102(a). 

  

	 	2.2.	“Board” means the Board of Directors of the Company, or any committee thereof, which was duly authorized by the Board of Directors, to exercise any or
all of the powers granted to the Board of Directors hereunder in accordance with and to the extent allowed by the provisions of the Companies Law. 

  

	 	2.3.	“Cause” means (i) conviction of any felony involving moral turpitude or affecting the Company; (ii) any refusal to carry out a directive of
the chief executive officer, the Board or the Optionee’s direct supervisor, which involves the business of the Company or its Affiliates and was capable of being lawfully performed; (iii) embezzlement of funds of the Company or its
Affiliates; (iv) any breach of the Optionee’s fiduciary duties or duties of care to the Company; including without limitation disclosure of confidential information of the Company; (v) any intentional material breach of the terms of
the Optionee’s employment agreement or other agreement with the Company and/or its Affiliates; and (vi) any conduct determined by the Board to be materially detrimental to the Company. 

 

	 	2.4.	“Company” means Evogene Ltd. 

  

	 	2.5.	“Companies Law” means the Israeli Companies Law, 5759-1999, as amended from time to time. 

 

	 	2.6.	“Controlling Shareholder” shall have the meaning ascribed to it in Section 32(9) of the Ordinance. 

  
 - 2 -

 EVOGENE 2013 SHARE OPTION PLAN 

 
  
  

	 	2.7.	“Date of Grant” means, the date of grant of an Option, as determined by the Board and set forth in the Optionee’s Option Letter of Agreement.

  

	 	2.8.	“Disability” shall mean the inability, due to illness, injury or mental condition to engage in any gainful occupation for which an individual is
qualified by education, training or experience, and such condition continues for at least six (6) months. 

  

	 	2.9.	“Employee” means a person who is employed by the Company or its Affiliates, including a director or an office holder, but excluding a Controlling
Shareholder. 

  

	 	2.10.	“Expiration Date” means the date upon which an Option shall expire, as set forth in Section 10.2 of the Plan. 

 

	 	2.11.	“Fair Market Value” means as of any date, the value of a Share determined as follows: 

(i) If Shares are listed on any established stock exchange or a national market system, including without limitation the
NASDAQ National Market system, or the NASDAQ SmallCap Market of the NASDAQ Stock Market, the Fair Market Value shall be the closing sales price for such Shares (or the closing bid, if no sales were reported), as quoted on such exchange or system for
the last market trading day prior to time of determination, as reported in the Wall Street Journal, or such other source as the Board deems reliable; 
 (ii) In the event sub-section (i) does not apply, the Fair Market Value thereof shall be determined in good faith by the Board. 

 

	 	2.12.	“Plan” means this Evogene Ltd. 2013 Share Option Plan, as amended from time to time. 

 

	 	2.13.	“ITA” means the Israeli Tax Authorities. 

  

	 	2.14.	“Non-Employee” means a consultant, adviser, service provider, Controlling Shareholder or any other person who is not an Employee.

  

	 	2.15.	“Option” means an option to purchase one Share that is granted pursuant to the Plan. 

 

	 	2.16.	“102 Option” means an Option granted to an Employee pursuant to Section 102(b) and held in trust by a Trustee for the benefit of the Optionee.

  

	 	2.17.	“3(i) Option” means an Option granted pursuant to Section 3(i) of the Ordinance. 

 

	 	2.18.	“Optionee” means a person who was issued an Option under the Plan. 

 

	 	2.19.	“Option Letter of Agreement” means the share option letter of agreement between the Company and an Optionee that sets out the principal terms and
conditions of an Option issue under the Plan, in the form attached as Annex A hereto. 

  

	 	2.20.	“Ordinance” means the Israeli Income Tax Ordinance [New Version], 1961, as amended from time to time. 

  
 - 3 -

 EVOGENE 2013 SHARE OPTION PLAN 

 
  
  

	 	2.21.	“Exercise Price” means the price-per-Share required to be paid by an Optionee in connection with the exercise of an Option. 

 

	 	2.22.	“Section 102” means section 102 of the Ordinance and any and all rules, regulations, orders and procedures promulgated thereunder, all as amended from
time to time. 

  

	 	2.23.	“Share” means an Ordinary Share, NIS 0.01 par value each, of the Company. 

 

	 	2.24.	“Successor Company” means, in the event of a Transaction that is a merger, the surviving entity, and in the event of a Transaction that is an
acquisition, the entity acquiring the Company’s issued share capital, in each case whether in a single Transaction or a series of related Transactions. 

 

	 	2.25.	“Transaction” means an acquisition of the Company, or a merger or reorganization of the Company with one or more other entities in which the Company is
not the surviving entity. 

  

	 	2.26.	“Trustee” means any individual appointed by the Company to serve as a trustee and approved by the ITA, all in accordance with the provisions of
Section 102(a). 

  

	 	2.27.	“Vested Option” means any Option, which has vested according to the Vesting Dates. 

 

	 	2.28.	“Vesting Dates” means, as determined by the Board, the date as of which the Optionee shall be entitled to exercise the Options or part of the Options,
as set forth in Section 11 of the Plan. 

  

	3.	ADMINISTRATION OF THE PLAN 

  

	 	3.1.	The Plan will be administered by the Board. Without derogating from any other power or authority granted to the Board elsewhere under the Plan or pursuant to applicable
law, the Board shall have the full authority in its sole and absolute discretion, from time to time and at any time, to determine: 

 (a) the identity of the Optionees; 
 (b) the number of Options to be granted to
each Optionee; 
 (c) the time or times at which the same shall be granted; 

(d) the Exercise Price, vesting schedule and other terms and conditions relating to the exercise of Options; 

(e) the schedule and conditions on which 102 Options and/or Shares issued upon exercise of 102 Options shall be released from the
Trustee; and/or 
 (f) any other matter that, in the Board’s sole and absolute discretion, is necessary or desirable for,
or incidental to, the administration of the Plan. Without derogating from the above, in determining the number of Options to be granted to each Optionee, the 

  
 - 4 -

 EVOGENE 2013 SHARE OPTION PLAN 

 
  
  

 
Board may consider, among other things, the Optionee’s salary, the duration of the Optionee’s employment by the Company, and the Optionee’s contribution to the Company. 

 

	 	3.2.	The Board may, from time to time, adopt such rules and regulations for carrying out the Plan as it may deem necessary. No member of the Board shall be liable for any
act or determination made in good faith with respect to the Plan or any Option granted hereunder. 

  

	 	3.3.	For the avoidance of doubt, the Board of Directors may delegate any and all of its powers hereunder to a committee thereof, subject to applicable law.

  

	 	3.4.	Each Option granted pursuant to the Plan shall be evidenced by a written Option Letter of Agreement between the Company and the Optionee. 

 

	 	3.5.	The interpretation and construction by the Board of any provision of the Plan or of any Option Letter of Agreement thereunder shall be final and conclusive.

  

	 	3.6.	No member of the Board shall be liable for any action or determination made in good faith with respect to the Plan or any Option granted hereunder.

  

	 	3.7.	The Board shall be entitled to grant Shares instead of Options, as it may deem desirable. The provisions of the Plan shall apply to such grant of Shares mutatis
mutandis. 

  

	4.	DESIGNATION OF OPTIONEES 

  

	 	4.1.	The persons eligible for participation in the Plan as Optionees shall include any Employees and/or Non-Employees of the Company or of any Affiliate; provided, however,
that (i) Employees may only be granted 102 Options; (ii) Non-Employees may only be granted 3(i) Options. 

  

	 	4.2.	The grant of an Option hereunder shall neither entitle the Optionee to participate nor disqualify the Optionee from participating in, any other grant of Options
pursuant to the Plan or any other option or share plan of the Company or any of its Affiliates. 

  

	 	4.3.	Anything in the Plan to the contrary notwithstanding, all grants of Options to directors and office holders shall be authorized and implemented in accordance with the
provisions of the Companies Law or any successor act or regulation, as in effect from time to time. 

  
 - 5 -

 EVOGENE 2013 SHARE OPTION PLAN 

 
  
  

	5.	ELECTION OF THE TAX TREATMENT FOR 102 OPTIONS GRANTED UNDER THE PLAN 

 

	 	5.1.	The Company hereby elects that commencing upon the first grant of 102 Options under this Plan and until otherwise elected by the Board, such election not to be effected
earlier than one year following the end of the year during which the Company first grants 102 Options under the Plan, all 102 Options that shall be granted to Employees under this Plan shall be granted pursuant to the capital gain tax track, in
accordance with the provisions of Section 102(b)(2), and shall be subject to the terms and conditions set forth in Section 102. Such election shall apply to all Optionees who shall be granted 102 Options during such period, all in
accordance with the provisions of Section 102(g). 

  

	 	5.2.	The Plan shall be filed with ITA for its approval at least 30 days before the first Date of Grant of any 102 Option hereunder. 

 

	 	5.3.	All 102 Options shall be held in trust by a Trustee, as described in Section 6 below. 

 

	 	5.4.	With regards to 102 Options, the provisions of the Plan and/or the Option Letter of Agreement shall be subject to the provisions of Section 102 and the Tax
Assessing Officer’s permit, and the said provisions and permit shall be deemed an integral part of the Plan and of the Option Letter of Agreement. Any provision of Section 102 and/or the said permit which is necessary in order to receive
and/or to keep any tax benefit pursuant to Section 102, which is not expressly specified in the Plan or the Option Letter of Agreement, shall be considered binding upon the Company and the Optionees. 

 

	6.	TRUSTEE 

  

	 	6.1.	All 102 Options that shall be granted under the Plan and any and all Shares allocated or issued upon exercise of such 102 Options and/or other shares received
subsequently following any realization of rights, including without limitation bonus shares, shall be allocated or issued to a Trustee and held by the Trustee for the benefit of the Optionees until the later of (i) such period of time as
required by Section 102 (the “Holding Period”), unless the ITA shall permit the release of such Options and/or Shares before the end of the Holding Period; and (ii) such date on which the Optionees shall instruct the
Trustee by written request to transfer such Options and/or Shares to themselves or to a third party. In case the requirements for the capital gain tax track are not met with respect to any 102 Options, then the tax treatment of such 102 Options
shall be as set forth in Section 102. 

  

	 	6.2.	Notwithstanding anything to the contrary, the Trustee shall not release any Shares allocated or issued upon exercise of 102 Options prior to the full payment of the
Optionee’s tax liabilities arising from 102 Options which were granted to him and/or any Shares allocated or issued upon exercise of such Options. 

  
 - 6 -

 EVOGENE 2013 SHARE OPTION PLAN 

 
  
  

	 	6.3.	The Trustee is released from any liability in respect of any decision and/or action with respect to the Plan, or any 102 Option or Share granted to the Trustee under
the Plan, which are taken and made by the Trustee in good faith. 

  

	 	6.4.	With respect to any 102 Option, subject to the provisions of Section 102, an Optionee shall not be entitled to sell or release from trust any Share received upon
the exercise of a 102 Option and/or any share received subsequently following any realization of rights, including without limitation, bonus shares, until the lapse of the Holding Period required under Section 102. Notwithstanding the above, if
any such sale or release occurs during the Holding Period, the sanctions under Section 102 shall apply to and shall be borne by such Optionee. 

  

	7.	SHARES RESERVED FOR THE PLAN AND THE RIGHTS ATTACHED THERETO; OPTIONS CONFER NO RIGHTS AS SHAREHOLDER 

 

	 	7.1.	The Company has reserved and shall reserve, from time to time, unissued Shares, for the purposes of the Plan, subject to adjustment as set forth in Section 9
below. Any Shares which remain unissued and which are not subject to outstanding Options at the termination of the Plan shall cease to be reserved for the purpose of the Plan, but until termination of the Plan the Company shall at all times reserve
sufficient number of Shares to meet the requirements of the Plan. Should any Option for any reason expire or be canceled prior to its exercise or relinquishment in full, the Share(s) subject to such Option shall remain reserved for the purposes of
the Plan and may be subjected to a different Option granted under the Plan. 

  

	 	7.2.	Subject to Sections 12.2 and 13.4 hereof, all Shares issued upon the exercise of Options issued under the Plan shall entitle the Optionee to all the rights attached to
the Shares of the Company, including the right to receive dividends with respect thereto and to vote the same at any meeting of the shareholders of the Company and all such shares shall be subject to the provisions of the Company’s Articles of
Association, as amended from time to time. 

  

	 	7.3.	For avoidance of any doubt, in respect of unexercised Options, the Optionees shall not be deemed for any purpose whatsoever to be shareholders of the Company and shall
have no rights or privileges of shareholders of the Company, nor shall they be deemed to be a class of shareholders, or creditors, of the Company for purpose of, inter alia, the operation of Sections 341, 350, 351 of the Companies Law and the
approvals of mergers thereunder and, for the avoidance of doubt and without derogating from the forgoing, Sections 184 and 185 of the Companies Law shall not apply to the Optionee in respect of unexercised Options. 

  
 - 7 -

 EVOGENE 2013 SHARE OPTION PLAN 

 
  
  

	8.	EXERCISE PRICE 

  

	 	8.1.	The Exercise Price of each Option shall be determined by the Board in its sole and absolute discretion in accordance with applicable law, including rules or regulations
promulgated by any stock exchange or national market system on which the Company’s securities are then being traded, and subject to any guidelines as may be determined by the Board from time to time. Each Option Letter of Agreement will contain
the Exercise Price determined for each Option. 

  

	 	8.2.	In accordance with the temporary directives of the Tel Aviv Stock Exchange that were approved in May 2012, as may be amended from time to time, and as long as such
directives remain in effect, anything in the Plan to the contrary notwithstanding, the per Share Exercise Price of any Option that is granted to Non-Employees, or to Employees who are Interested Parties (as such term defined in the Companies Law) in
the Company, shall not be less than ten (10) Agorot. 

  

	 	8.3.	The Exercise Price shall be payable upon the exercise of the Option in a form satisfactory to the Board, including without limitation, by cash or check. The Board shall
have the authority to postpone the date of payment on such terms as it may determine. 

  

	9.	ADJUSTMENTS 

 Upon the
occurrence of any of the following described events, Optionee’s rights to purchase Shares under the Plan shall be adjusted as hereafter provided: 
  

	 	9.1.	In connection with any Transaction, the Board shall have full power and authority to determine that all unexercised Options then outstanding under the Plan shall be
assumed or substituted by the Successor Company, for options to purchase shares of the Successor Company (or a parent or subsidiary of the Successor Company), which the Board determines, in its sole and absolute discretion, to be fair under the
circumstances. In the case of such assumption and/or substitution of Options, appropriate adjustments shall be made to the Exercise Price so as to reflect such action, and all other terms and conditions of the Option Letters of Agreement shall
remain unchanged, subject, however, to any further changes to the Letters of Agreement which may be made by the Board in accordance with the Plan, including pursuant to the provisions of this Section 9. Such adjustments to the Exercise Price
shall be made by the Board, whose determination in that respect shall be final, binding and conclusive. 

  

	 	9.2.	In connection with any Transaction, the Board shall have full power and authority to determine that all unexercised Options then outstanding under the Plan will be
substituted for any other type of asset or property, including cash, which the Board determines, in its sole and absolute discretion, to be fair under the circumstances. 

  
 - 8 -

 EVOGENE 2013 SHARE OPTION PLAN 

 
  
  

	 	9.3.	In connection with any Transaction or the sale of all or substantially all of the Company’s assets, the Board shall have full power and authority to determine:
(i) that the vesting of all or part of the Options outstanding and unvested at that time shall be accelerated so that any unvested Options or any portion thereof shall be vested immediately prior to the closing of the Transaction or the sale of
assets, and/or (ii) that any vested (including pursuant to subsection (i) above) and unexercised Option shall be automatically exercised by way of a Net Exercise immediately prior to, and subject upon, the closing of the Transaction.

 For the purpose of this Section 9.3 the term “Net Exercise” shall mean the exercise of an
Option for a number of Shares that shall be computed using the following formula: 
  

							
	 X
	 	 =	 	A-B	  	
				
		 		 	A	  	

 Where X = the number of Shares to be issued to the Optionee. 

A = the Fair Market Value of one Share. 
 B = the Exercise Price. 
 No fractional Shares shall be issued in connection with
a Net Exercise hereunder, but in lieu of such fractional shares the Company shall make a cash payment therefor upon the basis of the Fair Market Value of such Shares. 
  

	 	9.4.	If the Company is voluntarily liquidated or dissolved while unexercised Options remain outstanding under the Plan, the Company shall immediately notify all unexercised
Option holders of such liquidation, and the Option holders shall then have fourteen (14) days to exercise any unexercised Vested Option held by them at that time, in accordance with the exercise procedure set forth herein. However, if the
Company fails to notify any Option holders, it will only be liable to make provisions so that the rights of such Optionee in respect of unexercised Vested Option are not impaired or are substituted for any other type of asset or property, including
cash, which is fair under the circumstances. Upon the expiration of such fourteen-days period, all remaining outstanding Options will terminate immediately. 

 

	 	9.5.	 Subject to any required action by the shareholders of the Company, the number of outstanding Options as well as the Exercise Price of each such
outstanding Option, shall be proportionately adjusted for any increase or decrease in the number of issued Shares resulting from a split, reverse split, bonus share issuance, combination of the Shares or any other increase or decrease in the number
of issued Shares effected without receipt of any consideration by the Company. Such adjustment shall be made by the Board, whose determination in that respect shall be final, binding and conclusive. Except as expressly provided herein, no issuance
by the Company of shares of any class, or securities convertible into shares of any class, shall affect, and no adjustment by 

  
 - 9 -

 EVOGENE 2013 SHARE OPTION PLAN 

 
  
  

	 	
reason thereof shall be made with respect to, the number of outstanding Options and Exercise Price thereof, including without limitation, for any rights offering or dividend distribution.

  

	 	9.6.	In the event of a restructuring of the Company’s capital that is not regulated elsewhere under this Section 9, then upon the consummation of such
restructuring, each Optionee shall be entitled to purchase, subject to the conditions herein stated, such number of the Company’s replacement securities, as were exchangeable for, or have come instead of, the number of Shares, which such
Optionee would have been entitled to purchase except for such restructuring, and appropriate adjustments shall be made to reflect such action. 

  

	10.	TERM AND EXPIRATION; EXERCISE OF OPTIONS 

  

	 	10.1.	Options shall be exercised by the Optionee by giving written notice to the Company and/or to any third party designated by the Company (the
“Representative”), in such form and method as may be determined by the Company and when applicable, by the Trustee in accordance with the requirements of Section 102, which exercise shall be effective upon receipt of such
notice by the Company and/or the Representative and the payment of the Exercise Price at the Company’s or the Representative’s principal office. The notice shall specify the number of Shares with respect to which the Option is being
exercised. In connection with an exercise of an Option or any other matter, the Company shall not be obligated to provide the Optionee with any information or documents as to the financial or business condition of the Company, or otherwise provide
information as to the condition of the Company in general. 

  

	 	10.2.	Options, to the extent not previously exercised, shall terminate forthwith upon the earlier of: (i) the date set forth in the Option Letter of Agreement and if
such date is not set, then ten years from the Date of Grant thereof; and (ii) the expiration of any extended period in any of the events set forth in Section 10.5 below. 

 

	 	10.3.	Subject to Section 10.7 below, the Options may be exercised by the Optionee in whole at any time or in part from time to time, to the extent that the Options
become vested and exercisable, prior to the Expiration Date, and provided that, subject to the provisions of Section 10.5 below, the Optionee is employed by or providing services to, as applicable, the Company or any of its Affiliates at all
times during the period beginning with the granting of the Option and ending upon the date of exercise. 

  

	 	10.4.	 Subject to the provisions of Section 10.5 below, in the event of termination of Optionee’s employment or services, as applicable, with the
Company or any of its Affiliates, all Options granted to such Optionee will immediately, ipso facto, expire. For the avoidance of doubt, in case of such termination of employment or service, the unvested portion of the Optionee’s Option shall
not vest and shall not 

  
 - 10 -

 EVOGENE 2013 SHARE OPTION PLAN 

 
  
  

	 	
become exercisable. For the purpose of this Section 10, the transfer of an Optionee from the employ or service of the Company to the employ or service of an Affiliate or between Affiliates
shall not be deemed to be a termination of Optionee’s employment or services. 

  

	 	10.5.	Notwithstanding anything to the contrary hereinabove and unless otherwise determined in the Optionee’s Option Letter of Agreement, an Option may be exercised after
the date of termination of Optionee’s employment or service, as applicable, with the Company or any Affiliates, during an additional period of time beyond the date of such termination, but only with respect to Vested Options at the time of such
termination, if: 

 (i) termination is without Cause, in which event any Vested Option still is in force and
unexpired may be exercised within a period of ninety (90) days after the date of such termination; or 
 (ii) termination
is the result of death or Disability of the Optionee, in which event any Vested Option still in force and unexpired may be exercised within a period of twelve (12) months after the date of such termination; or 

(iii) the Board shall authorize an extension of the terms of all or part of the Vested Options beyond the date of such termination, but
in no event beyond the expiration date of the Vested Options. 
 For avoidance of any doubt, if termination of employment or
service, as applicable, is for Cause, any outstanding unexercised Option (whether vested or non-vested), will immediately expire and terminate, and the Optionee shall not have any right in connection to such outstanding Options. 

 

	 	10.6.	Any form of Option Letter of Agreement authorized by the Plan may contain such other provisions as the Board may, from time to time, deem advisable.

  

	 	10.7.	For as long as the Shares are traded on the Tel Aviv Stock Exchange, pursuant to the regulations of the Tel Aviv Stock Exchange, as may be amended from time to time, no
Options may be exercised on the record date for distribution of bonus shares, rights offering, dividend distribution, capital consolidation, capital split or reduction of capital (each such event a “Company Event”). Additionally, in
the event the X day (as such term defined in the Companies Guidebook published by the Tel Aviv Stock Exchange) of a Company Event occurs before the record date of such Company Event, no Options may be exercised on such X day.

  

	11.	VESTING OF OPTIONS 

  

	 	11.1.	Subject to the provisions of the Plan, each Option shall vest following the Vesting Dates and for the number of Shares as shall be provided in the Option Letter of
Agreement. However, no Option shall be exercisable after the Expiration Date. 

  
 - 11 -

 EVOGENE 2013 SHARE OPTION PLAN 

 
  
  

	 	11.2.	Unless the Board provides otherwise, vesting of Options shall be suspended during any unpaid leave of absence, other than, in the case of any (a) leave of absence
which was pre-approved by the Company for purpose of continuing the vesting of Options, or (b) transfers between locations of the Company or between the Company, any Affiliate, or any respective Successor Company thereof.

  

	 	11.3.	An Option may be subject to such other terms and conditions on the time or times when it may be exercised, as the Board may deem appropriate. The vesting provisions of
individual Options may vary. 

  

	12.	DIVIDENDS 

  

	 	12.1.	With respect to all Shares (but excluding, for avoidance of any doubt, any unexercised Options) allocated or issued upon the exercise of Options by the Optionee and
held by the Optionee or by the Trustee, as the case may be, the Optionee shall be entitled to receive dividends in accordance with the quantity of such Shares, subject to the provisions of the Company’s Articles of Association (and all
amendments thereto) and subject to any applicable taxation on distribution of dividends, and when applicable subject to the provisions of Section 102. 

 

	 	12.2.	With respect to Shares held by the Trustee on behalf of an Optionee, cash dividends or dividends in kind or assets shall be paid or distributed directly to the
Optionee, after withdrawing applicable taxes. However, all share dividends and/or bonus shares and/or securities of the Company issued and/or distributed to the Optionee with respect to Shares held by the Trustee on behalf of a Optionee shall be
remitted to the Trustee, which shall hold the same for the benefit of such Optionee until the Shares are released from trust pursuant to Section 6 above, and such share dividends, bonus shares or securities of the Company shall be subject to
the provisions of Section 102. 

  

	13.	RESTRICTIONS ON TRANSFERABILITY AND SALE OF OPTIONS; LOCK UP 

  

	 	13.1.	No Option shall be assignable or transferable by the Optionee to whom it is granted other than by will or the laws of descent and distribution, and an Option may be
exercised during the lifetime of the Optionee only by such Optionee or by such Optionee’s guardian or legal representative. The terms of the Option shall be binding upon the beneficiaries, executors, administrators, heirs and successors of such
Optionee. 

  

	 	13.2.	As long as Options and/or Shares are held by the Trustee on behalf of the Optionee, all rights of the Optionee over the Shares are personal, cannot be transferred,
assigned, pledged or mortgaged, other than by will or pursuant to the laws of descent and distribution. 

  
 - 12 -

 EVOGENE 2013 SHARE OPTION PLAN 

 
  
  

	 	13.3.	Transfer and sale of the Shares that are issuable upon exercise of Options is subject to the provisions of the Company’s Articles of Association as amended from
time to time and applicable law, including without limitation, restrictions on resale pursuant to the provisions of the Israeli Securities Law, 5728-1968 and the regulations promulgated thereunder. 

 

	 	13.4.	In connection with any public offering of the Company’s securities, Optionee’s rights to sell the Shares may be subject to certain limitations (including a
lock-up period) as may be required by applicable law, including rules or regulations promulgated by any stock exchange or national market system on which the Company’s securities are being traded, and/or as may be requested by the Company or
its underwriters, and the Optionees are required to comply with any such limitations and cooperate with the Company and to sign any document that may be required by the underwriters in such respect. 

 

	14.	EFFECTIVE DATE 

 The Plan
shall be effective as of the day it was adopted by the Board. 
  

	15.	AMENDMENTS OR TERMINATION OF THE PLAN 

 The Board may, at any time, amend, alter, suspend or terminate the Plan. No amendment, alteration, suspension or termination of the Plan shall impair the rights of any Optionee, unless mutually agreed
otherwise between the Optionee and the Company. Termination of the Plan shall not affect the Board’s ability to exercise the powers granted to it hereunder with respect to Options granted under the Plan prior to the date of such termination.

  

	16.	CONTINUANCE OF EMPLOYMENT OR HIRED SERVICES 

 Neither the Plan nor the Option Letter of Agreement with the Optionee shall impose any obligation on the Company or an Affiliate thereof, to continue any Optionee in its employ or service, and nothing in
the Plan or in any Option granted pursuant thereto shall confer upon any Optionee any right to continue in the employ or service of the Company or an Affiliate thereof or restrict the right of the Company or an Affiliate thereof to terminate such
employment or service at any time. 
  

	17.	GOVERNING LAW & JURISDICTION 

 The Plan, the granting and exercise of Options hereunder, and the obligation of the Company to sell and deliver Shares under such Options, shall be governed by and construed and enforced in accordance
with the laws of the State of Israel, without giving effect to the principles of conflict of laws thereof. The competent courts in Tel-Aviv, Israel shall have sole jurisdiction in any dispute pertaining to the Plan, the granting and exercise of
Options hereunder, and the obligation of the Company to sell and deliver Shares under such Options. 

  
 - 13 -

 EVOGENE 2013 SHARE OPTION PLAN 

 
  
  

	18.	TAX CONSEQUENCES 

  

	 	18.1.	Any tax consequences arising from the grant or exercise of any Option, from the payment for Shares covered thereby or from any other event or act (of the Company and/or
its Affiliates, the Trustee or the Optionee), hereunder, shall be borne solely by the Optionee. The Company and/or its Affiliates and/or the Trustee shall withhold taxes according to the requirements under the applicable laws, rules, and
regulations, including withholding taxes at source. Furthermore, the Optionee shall agree to indemnify the Company and/or its Affiliates and/or the Trustee and hold them harmless against and from any and all liability for any such tax or interest or
penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to the Optionee. 

 

	 	18.2.	The Company and/or, when applicable, the Trustee shall not be required to release any Share certificate to an Optionee until all required payments have been fully made.

  

	19.	NON-EXCLUSIVITY OF THE PLAN 

 The adoption of the Plan by the Board shall not be construed as amending, modifying or rescinding any previously approved incentive arrangements or as creating any limitations on the power of the Board to
adopt such other incentive arrangements as it may deem desirable, including, without limitation, the granting of Options otherwise than under the Plan, and such arrangements may be either applicable generally or only in specific cases. 

For the avoidance of doubt, prior grant of options to Optionees of the Company under their employment agreements, and not in the
framework of any previous option plan, shall not be deemed an approved incentive arrangement for the purpose of this Section. 
  

	20.	APPLICATION OF FUNDS 

The proceeds received by the Company from pursuant to the exercise of Options granted under the Plan will be used for general corporate
purposes of the Company, or as otherwise determined by the Board in its sole and absolute discretion. 
  

	21.	MULTIPLE AGREEMENTS 

 The
terms of each Option may differ from other Options granted under the Plan at the same time, or at any other time. The Board may also grant more than one Option to a given Optionee during the term of the Plan, either in addition to, or in
substitution for, one or more Options previously granted to that Optionee. 

  
 - 14 -EX-10.2

 EXHIBIT 10.2 
 Share Purchase Agreement 
 This Share Purchase Agreement (the
“Agreement”) is made and entered into as of this 27 day of August, 2008, by and among Evogene Ltd., a company organized under the laws of the State of Israel (the “Company”) and Monsanto Company, a company
organized under the laws of Delaware (the “Purchaser”). 
  

			
	WHEREAS	  	The Company is a publicly-traded company whose securities are listed for trade on the Tel Aviv Stock Exchange Ltd. (hereinafter the “TASE”); and
		
	WHEREAS	  	The Purchaser desires to invest in the Company an amount of up to US$30,000,000 (the “Aggregate Investment”) in two (2) tranches in consideration for up to
5,000,000 Ordinary Shares (as defined below) of the Company, as more particularly set out in this Agreement;

 Now, therefore, in consideration of the mutual promises and covenants set forth herein, the Parties
hereby agree as follows: 
  

	1.	Preamble, Appendices and Interpretation 

  

	 	1.1	The preamble and the Appendices to this Agreement constitute an integral part hereof and are to be read as one with the remaining clauses thereof.

  

	 	1.2	In this Agreement, unless otherwise expressly stated, the terms set out below shall bear the meaning appearing opposite them: 

 

	 	1.2.1	“Closing” - The closing of the purchase and sale of the Purchased Shares (as defined below) which shall take place by teleconference, facsimile and
electronic mail communication within four (4) United States business days from the receipt of the approvals set-forth in Section 5 below or at such other time and place as may be agreed between the Parties (the “Closing
Date”). 

  

	 	1.2.2	“Purchased Shares” - means 3,272,727 Ordinary Shares having a par value of NIS 0.01 each of the Company listed for trade on the TASE.

  

	 	1.2.3	The “Prospectus” - the Company’s prospectus dated May 30, 2007. 

 

	 	1.2.4	“Price Per Share” – USD 5.50 

  

	 	1.2.5	“Collaboration Agreement” - 2008 Collaboration and License Agreement between the Parties dated August 27, 2008 relating to developing transgenic
yield and stress traits in certain agricultural crops. 

  

	 	1.2.6	“Regulations” – the regulations that were promulgated under the Securities Law. 

 

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

	 	1.2.7	“Securities Law” – the Israeli Securities Law -1968. 

 

	 	1.2.8	“Taxes” - all taxes imposed by any jurisdiction, including, without limitation, income, employment, value-added taxes, withholding, Social Security (or
the equivalent thereof), custom duties, obligatory registration fee, and other taxes, governmental fees or like charges of any kind whatsoever, including any interest, penalties, fines or additions thereto, whether disputed or not.

  

	2.	The Investment 

 Subject
to the terms and conditions hereof, the Company shall issue, sell and deliver to the Purchaser, and the Purchaser shall purchase from the Company, the Purchased Shares against payment by the Purchaser of an aggregate amount of US$18,000,000
(hereinafter the “Investment Amount”). 
  

	3.	Representations of the Company 

 The Company hereby declares and represents as follows: 
  

	 	3.1	The Company is a public company (as such term is defined in the Israeli Companies Law, 5759-1999) registered in Israel, the shares of which are listed for trade on the
TASE. 

  

	 	3.2	The Company has received no valid notice from the TASE of any intention to delist its securities from trading and/or transfer the Company’s securities to a watch
list, and has no reason to believe that the issuance of the Purchased Shares and/or the Additional Shares would cause any of the Company’s securities to be delisted from trading or transferred to a watch list. 

 

	 	3.3	The Company has filed with the Israel Securities Authority (the “ISA”) and the TASE all the required reports and notices in accordance with the
Securities Law and the Regulations (hereinafter the “Reports”). Except as set forth in the Reports and except for normal liabilities arising in the ordinary course of business consistent with past practice, the Company does not have
any liabilities, either accrued, contingent or otherwise, whether due or to become due, that individually or in the aggregate have had or would reasonably be expected to have a material adverse effect on the Company. 

 

	 	3.4	 The Prospectus and the annual report of the Company for the year 2007 and the Reports filed by the Company since the publication thereof (collectively,
the “Periodic Report”) are incorporated herein by reference, were true, accurate and complete as of the date filed with the TASE and/or the ISA, as applicable, contain all the information that is necessary for a reasonable investor
considering purchasing securities of the Company at the time of their publication and as of the date hereof, and no material information was omitted therefrom, except for 

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -2-

	 	
information concerning this Agreement, the Collaboration Agreement and a prospective collaboration agreement in Africa in the field of Biodiesel, the publications of which were postponed in
accordance with the Securities Law and the Regulations and which were disclosed to the Purchaser, the absence of which could mislead a reasonable investor. There has been no material adverse change to the Company’s business, market or financial
condition since the date of the Periodic Report. The Company will make copies of all such reports available to Purchaser in the English language after the Closing. 

 

	 	3.5	The registered share capital of the Company is NIS 3 million divided into 300,000,000 ordinary shares of NIS 0.01 par value each (hereinafter “Ordinary
Shares”). 

  

	 	3.6	As of the date of this Agreement, the Company’s share capital consists of the following securities: 

 

	 	3.6.1	20,808,568 Ordinary Shares listed for trade on the TASE; 

  

	 	3.6.2	3,900,000 Series 1 Warrants listed to trade on the TASE (hereinafter “Series 1 Warrants”) exercisable into 3,900,000 Ordinary Shares;

  

	 	3.6.3	4,551,584 Series 2 Warrants listed to trade on the TASE (hereinafter “Series 2 Warrants”) exercisable into 4,551,584 Ordinary Shares listed to trade on
the TASE; 

  

	 	3.6.4	4,387,556 non-tradable options exercisable into 4,387,556 Ordinary Shares that were previously granted to investors, employees, consultants and directors of the
Company. 

 Detailed capitalization tables immediately prior to and subsequent to the Closing are attached hereto
as Exhibit 3.6.4. 
  

	 	3.7	The Purchased Shares and the Additional Shares (as defined below) will rank equally in all respects with the existing Ordinary Shares. 

 

	 	3.8	 The Company has the full corporate power and authority to execute and deliver this Agreement and to consummate the transactions contemplated hereby.
Except as set forth in Sections 5, 7 & 8 below, no consents, approvals, authorizations or permits are required in connection with the consummation by the Company of the transactions contemplated by this Agreement. The Company has duly and
validly executed and delivered this Agreement, and assuming compliance by the Purchaser herewith, this Agreement when executed by the Company will constitute valid, binding and enforceable obligations of the Company in accordance with its terms.
Neither the execution of this Agreement, nor the performance of the terms thereof, nor the consummation of the transactions contemplated thereby will conflict with, or result in a violation of, or constitute a

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -3-

	 	
default under the foundation documents of the Company, or any agreement or other instrument to which the Company is a party or by which it is bound, or to which any of its properties is subject,
nor will the performance by the Company of its obligations hereunder violate any law, consent, permit, rule, regulation or order of any court, or any governmental agency or body having jurisdiction over the Company or any of its properties. Such
execution and compliance will not give to others any rights, including, but not limited to, rights of termination, cancellation or acceleration, in or with respect to any agreement or commitment referred to in this section, or to any of the
properties of the Company. 

  

	 	3.9	To the best of the Company’s knowledge, no voting agreements exist among its Shareholders. 

 

	 	3.10	The Company owns, or has the right to use, all patents, patent applications, trademarks, service marks, copyrights, trade secrets, know-how, inventions, designs,
processes and computer programs (collectively, the “Intellectual Property”) used in the conduct of its business as currently conducted and as proposed to be conducted. In its conduct of certain research activities, the Company uses
certain third-parties’ Intellectual Property without obtaining a license thereto, such use being based upon an exemption in the Israeli Patents Law, 1967 permitting experimental activities regarding an invention the aim of which is to improve
an invention or to develop another invention, provided such activities are not of a businesslike scope or nature, and that prior to development and commercialization of a product using such third party Intellectual Property, the Company or its
collaborators shall acquire appropriate licenses. 

  

	 	3.11	Except as set forth in Exhibit 3.11 attached hereto, the Company has not received any notice from any person or entity asserting that the Company
infringes the Intellectual Property rights of such person or entity and, to the Company’s knowledge, the Company is not infringing and has not infringed upon the Intellectual Property rights of such person or entity. 

 

	 	3.12	All employees of the Company and former employees thereof have assigned and are obligated to assign to the Company all Intellectual Property rights developed by them in
the course of their employment with the Company. 

  

	 	3.13	The Company is not committed to pay to any third party any broker’s or finder’s fee or any other similar commission or fee in connection with the investment
contemplated hereunder. 

  

	 	3.14	 The Company has filed all Tax returns and reports that it is required to file, paid all Taxes that are due and payable, and paid or accrued all Taxes
for which a notice of assessment or collection has been received. No Taxing authority has asserted any claim for Taxes, or is threatening any claim for Taxes that would have a material adverse effect on the Company. The Company has withheld and paid
over to appropriate governmental authorities or are holding for payment all 

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -4-

	 	
Taxes required by law to have been withheld or collected. There are no liens for Taxes on the assets of the Company other than liens that individually or in the aggregate would not have a
material adverse effect. No jurisdiction in which the Company does not file Tax returns has claimed that the Company is required to file Tax returns or pay Taxes in such jurisdiction. 

 

	 	3.15	Except as described in the Reports and in this Agreement (including the exhibits hereto), there is no action, suit or proceeding, claim, arbitration or investigation
against the Company pending, or to the Company’s knowledge, threatened that individually or in the aggregate has had or reasonably would be expected to have a material adverse effect on the Company. 

 

	 	3.16	The Company has complied with, is not in violation of, and has not received any notices of violation with respect to any statute, law or regulation with respect to the
conduct of its business, except for failures that, individually or in the aggregate, have not had or would not reasonably be expected to have a material adverse effect on the Company. 

 

	 	3.17	The Company has all permits, licenses and any similar authority necessary for the conduct of its business or ownership of property, other than as would not have a
material adverse effect on the Company. 

  

	 	3.18	The operations and other properties of the Company are, and at all times within the period of the applicable statute of limitations (giving effect to any waiver,
mitigation or extension thereof) have been, in compliance in all material respects with, and not subject to pending or threatened liability under, all applicable environmental laws and permits issued thereunder. No substance identified or regulated
pursuant to any environmental law, including, without limitation, any hazardous substance, hazardous waste, toxic substance, pollutant, contaminant or petroleum or any fraction thereof, has been released in a reportable quantity or has otherwise
come to be located on, at, proximate to or beneath any real property currently or formerly operated, leased, or used by any Acquired Company. No facts or circumstances exist and no event or condition is occurring or has occurred with respect to the
Company relating to any environmental law, any release of any hazardous substance, or the Company’s compliance with current requirements of environmental law, that, individually or in the aggregate, have had or could reasonably be expected to
have a material adverse effect on the Company. 

  

	 	3.19	 Neither the Company nor its directors, officers, employees or agents, or any other person acting on their behalf, directly or indirectly, has to the
knowledge of the Company, given or agreed to give any gift or similar benefit to any customer, supplier, governmental employee or any other person that (i) could reasonably be expected to subject the Company to any damage or penalty in any
civil, criminal or governmental litigation or proceeding, except for such damages or penalties as could not, individually or in the aggregate, reasonably be expected to have a material adverse effect, (ii) if not given in the past, might have
had a material 

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -5-

	 	
adverse effect or (iii) if not continued in the future, might have a material adverse effect or that might subject the Company to suit or penalty in any private or governmental litigation or
proceeding, except for such suit or penalty as could not, individually or in the aggregate, reasonably be expected to have a material adverse effect. 

  

	 	3.20	The Company has not breached, or received in writing any claim or notice that it has breached, any of the terms or conditions of any material agreement, contract or
commitment in such manner that has had or would reasonably be expected to have a material adverse effect on the Company. Each material contract of the Company that has not expired by its terms is in full force and effect. 

 

	 	3.21	The Company is in compliance in all material respects with all applicable laws, policies, procedures and agreements relating to employment, terms and conditions of
employment and to the proper withholding and remission to the proper tax authorities of all sums required to be withheld from employees or persons deemed to be employees under applicable tax laws. Except as provided in the Reports, the Company has
paid all of its employees all wages, salaries, commissions, bonuses, benefits and other compensation due and payable to such employees on or prior to the date hereof. All of Company’s employees are parties to employment agreements,
non-competition and confidentiality agreements with the Company, and all of the Company’s consultants who have access to the Company’s technical intellectual property (i.e., not including the Company’s executive summary and business
plan) are subject to consulting agreements and confidentiality agreements with the Company. 

  

	 	3.22	Except as described in the Reports, there are no transactions or proposed transactions between the Company and any other person or entity that is at the date of such
transaction or at the date of this Agreement an Interested Party (as defined in the Israeli Companies Law – 1999), and no Interested Party, employee, shareholder, officer or director of the Company is indebted to the Company, nor is the Company
indebted (or committed to make loans or extend or guarantee credit) to any of them. 

  

	 	3.23	Except as set forth in the Reports, the Company holds all of its real and personal property free and clear of all liens, mortgages or other encumbrances. All
improvements on such property are in good condition and all mechanical and utility systems serving such improvements are in good condition, free of material defects. 

 

	 	3.24	Within the meaning of 16 CFR 802.51, the Company did not, in its most recent fiscal year, have aggregate sales in or into the United States in excess of US$63,000,000,
and the Company does not hold assets located in the United States (including exclusive patent (or patentable) rights) with an aggregate fair market value in excess of US$63,000,000. 

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -6-

	4.	Representations of the Purchaser 

 The Purchaser hereby represents and warrants as follows: 
  

	 	4.1	It is a public company formed under the laws of the State of Delaware, whose securities are listed for trade on the NY Stock Exchange (the “NYSE”).

  

	 	4.2	It has the full corporate power and authority to execute and deliver this Agreement and to consummate the transactions contemplated hereby. The Purchaser has duly and
validly executed and delivered this Agreement, and assuming compliance by the Company herewith, this Agreement when executed by the Purchaser will constitute valid, binding and enforceable obligations of the Purchaser in accordance with its terms.

  

	 	4.3	It has sufficient immediately available funds in cash to pay the Investment Amount and to satisfy any other obligations hereunder and in connection with the
transactions contemplated hereby on the terms and conditions as set forth herein. 

  

	 	4.4	It is aware that the Purchased Shares and the Additional Shares (as defined in Section 7 below) are and will be subject to Section 15 of the Securities Law
and the Securities Law Regulations (Details with Regard to Sections 15A to 15C of the Law), 2000, which imposes certain restrictions in respect of the tradability of the Purchased Shares and the Additional Shares. 

 

	 	4.5	On the date of this Agreement, it does not hold any securities of the Company, directly or indirectly. 

 

	 	4.6	No written or oral agreement or voting agreement exists between the Purchaser and any of the holders of the other securities of the Company or any other person or
entity concerning their rights and/or holdings in the Company. 

  

	 	4.7	It is a company incorporated under the laws of Delaware. No consents, approvals, authorizations or permits are required in connection with the consummation by the
Purchaser of the transactions contemplated by this Agreement. 

  

	 	4.8	The Purchaser will, promptly after execution of this Agreement by both parties, deliver to the Company in English all data listed in Exhibit 4.8 attached
hereto for the purpose of publishing immediate reports pursuant to the Securities Law Regulations (Private Offering of Securities in a Listed Company), 2001 (the “Private Offering Regulations”) and the Securities Law Regulations
(Periodic and Immediate Statements), 1970. In the event that the Company shall be required by applicable law to provide additional information to that listed in Exhibit 4.8 for the purpose of publishing immediate reports, then the Purchaser shall
provide the Company with any such additional information; provided, however, that the Company shall provide reasonable assistance to Purchaser should Purchaser wish to approach a court or applicable regulatory authority to determine whether such
additional information is required to be submitted and/or whether it may be submitted on a confidential basis. 

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -7-

	5.	Conditions Precedent; Pre-Closing Conduct 

  

	 	5.1	It is hereby agreed that the consummation of the investment and the issuance of the Purchased Shares under this Agreement are subject to (i) the approval of the
Investment Center of the Ministry of Industry, Trade and Employment; (ii) the approval of the TASE to list the Purchased Shares for trading (the “TASE Approval”), (iii) the absence or completion of any premerger
notification obligations or investigations under the competition laws of the State of Israel and the US, (iv) the execution by both parties of the Collaboration Agreement, and (v) the absence of a material adverse effect on the
Company’s business, market or financial condition other than general economic or political conditions (hereinafter, “Material Adverse Effect”), during the period between signing of this Agreement and the Closing Date.

  

	 	5.2	Until the Closing the Company shall conduct its business solely in the ordinary course of business and, among other things, shall not declare or make any distribution
to its shareholders, enter into any related party transaction, or sell or grant an exclusive license to any material asset (other than to the Company’s products sold in the ordinary course of business). 

 

	 	5.3	Until the Closing neither the Company nor any agent of the Company shall solicit, initiate or encourage the submission of an inquiry, contact, proposal or offer
relating to a possible merger, sale or other disposition of a material asset of the Company or relating to a possible sale of, investment in, or issuance of, its capital stock or relating to matters that are the subject of the Collaboration
Agreement, or participate in any discussions or negotiations regarding, or furnish information with respect to, participate in, or facilitate in any other manner any of the foregoing, without the prior consent of the Purchaser.

  

	 	5.4	Until the Closing, the Company shall provide to Purchaser, in advance of publication, a translation into English of any immediate report, press release or public
statement prepared by the Company with respect to the transactions contemplated hereby and all such statements shall be subject to Purchaser’s approval, subject to the requirements of applicable law and regulations. 

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -8-

	6.	Closing & Post Closing 

 A. Closing 
 Subject to the receipt of the approvals described in
Section 5 above, the parties will convene on the Closing Date by teleconference, facsimile and electronic mail communication, for the purpose of completing the transaction as described in Section 2 above. On the Closing Date, the following
actions will be taken: 
  

	 	6.1	The Purchaser will furnish the Company with details of an account in which the Purchased Shares will be deposited under this Agreement and which enables the trade of
the Purchased Shares on the TASE, including the name of the holder of the account, the account number and the name of the stock exchange member with whom the account is maintained (hereinafter the “Account”).

  

	 	6.2	The Purchaser will wire transfer the Investment Amount in U.S. dollars to the Company’s bank account as detailed below: 

First International Bank 
 Swift Code: FIRBILITXXX 
 Ramat Hachayal Branch, Branch no. 121 

Payable to: Evogene Ltd. 
 Account no. [* * *] 
 Bank telephone number: +972-3-768-0200 

Bank facsimile number: +972-3-649-5988 
  

	 	6.3	The Purchaser will deliver to the Company an executed copy of an Undertaking towards the Israeli Chief Scientist of the Ministry of Industry, Trade and Employment (the
“OCS”) substantially in the form attached hereto as Exhibit 6.3 or in any other form required by the OCS. 

  

	 	6.4	The Company shall deliver to the Purchaser a letter from the Company’s Chief Executive Officer confirming that (i) the Board of Directors of the Company has
approved the issuance of the Purchased Shares to the Purchaser, (ii) the Company’s representations and warranties herein are true and correct and the Company’s covenants herein have been fulfilled at Closing and (iii) there has
been no Material Adverse Effect on the Company during the period between signing of this Agreement and the Closing Date and a letter from the Chairman of the Company’s Board of Directors pursuant to Section 282 of the Israeli Companies Law
– 1999 confirming that all approvals required by the Company for the issuance of the Purchased Shares have been obtained (the “Company Letter”). 

 

	 	6.5	The Company shall deliver to the Purchaser a copy of the share certificate registered in the name of Bank Leumi le-Israel Nominees Company Ltd., (hereinafter the
“Nominees Company”) representing the Purchased Shares (the “Share Certificate”), a copy of the approval by the Tel Aviv Stock Exchange of registration of the Purchased Shares for trading, and a copy of the
Company’s immediate report with respect to the issuance of the shares. 

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -9-

 B. Post Closing 

 

	 	6.6	The Company undertakes to deliver to the Nominees Company promptly after receipt of the Investment Amount, the Share Certificate and other documentation necessary to
enable the trade of the Purchased Shares. 

  

	 	6.7	As of the appointment of the Purchaser’s Director in accordance with the provisions of Section 8 below, and as long as the Purchaser’s Director is a
member of the Company’s board of directors, the Company shall maintain Directors and Officer liability insurance policy in an amount of no less than US$10,000,000. 

 

	 	6.8	The Company undertakes to use reasonable efforts to provide the Purchaser with English translations of its quarterly and annual periodic reports and of other
substantial and material filings with the Israel Securities Authority and/or the TASE. 

  

	7.	Put Option 

  

	 	7.1	Subject to the Company fulfillment of its Diligence Obligations to be completed by the third anniversary of the Closing pursuant to the Collaboration Agreement, and
subject to the Company issuing a letter from the Company’s Chief Executive Officer confirming that the Board of Directors of the Company has approved the issuance of the Additional Shares (as defined below) to the Purchaser and a letter from
the Chairman of the Company’s Board of Directors pursuant to Section 282 of the Israeli Companies Law – 1999 confirming that all approvals required by the Company for the issuance of the Additional Shares have been obtained, the
Purchaser hereby irrevocably grants the Company an option (hereinafter the “Put Option”) pursuant to which the Company may issue to the Purchaser 1,727,273 Ordinary Shares of the Company (hereinafter the “Additional
Shares”) at a price of USD 6.9473 per Additional Share, that will be paid in US dollars by the Purchaser (hereinafter the “Exercise Price”), for an aggregate consideration of up to US$12,000,000; provided, however,
that the average price per share of the Aggregate Investment shall be $6 per share. Partial exercise of the Put Option shall be subject to the written consent of the Parties. 

 

	 	7.2	Exercise of the Put Option may be made by the Company as of the third anniversary of the Closing and for a period of thirty (30) days thereafter by notice in
writing of the Company to the Purchaser (hereinafter the “Exercise Notice”). 

  

	 	7.3	Immediately after delivery of the Exercise Notice, the Company will proceed to publish an immediate report (‘current report’) pursuant to the Private Offering
Regulations and obtain the approval of the TASE to list the Additional Shares for trading. 

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -10-

	 	7.4	The parties will, within four (4) US business days of the date of receiving the TASE approval mentioned in clause 7.3 above, convene by teleconference, facsimile
and electronic mail communication, and take the following action: 

  

	 	7.4.1	The Purchaser will furnish to the Company details of the account in which the Additional Shares will be deposited if such details are changed compared to those of the
account conveyed according to clause 6.1 above. 

  

	 	7.4.2	The Purchaser will wire transfer the Exercise Price to the Company’s bank account as detailed in Section 6.2 above or to such other bank account as shall be
detailed in the Exercise Notice. 

  

	 	7.4.3	The Company shall deliver to the Purchaser the copy of a share certificate registered in the name of the Company’s nominees company at such time representing the
Additional Shares. 

  

	 	7.4.4	Upon receipt of the Exercise Price, the Company undertakes to deliver to its nominees company the share certificate and other documentation necessary to enable the
trade of the Additional Shares. 

  

	8.	Representation on the Board 

  

	 	8.1	Upon the consummation of the Closing, the Company’s Board of Directors will appoint a person who was recommended by the Purchaser and who is not an employee of the
Purchaser or any of its affiliates as a director (hereinafter: the “Purchaser’s Director”), to the Company’s Board of Directors according to Article 19.8 of the Company’s Articles of Association in effect on the date
hereof, and resolve to convene a special general meeting on which agenda will appear the appointment of the Purchaser’s Director. 

  

	 	8.2	Upon receipt of the general meeting’s approval of the appointment of the Purchaser’s Director and during the Exclusivity Period (as such term is defined in
the Collaboration Agreement) and also thereafter, as long as the Purchaser holds at least 5% of the voting rights in the Company, but only for as long as the Company implements the staggered board mechanism set-forth in Article 19.1 of its Articles
of Association in effect as of the date hereof, then upon the Purchaser ‘s Director retirement from the Board of Directors in accordance with the provisions of Article 19.1, the Company’s Board of Directors shall recommend to the general
meeting of the Company to reappoint the Purchaser ‘s Director to the Company’s Board of Directors. 

  

	 	8.3	 In the event the general meeting of the Company resolves not to appoint the Purchaser’s Director to the Company’s Board of Directors, then,
as from such general meeting and for the duration of the Exclusivity Period (as such term is defined in the Collaboration Agreement) and also thereafter, as long as the Purchaser holds 5% of the voting rights in the Company, the Purchaser will be

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -11-

	 	
entitled to appoint an observer at meetings of the Company’s Board of Directors who shall not be an employee of the Purchaser or any of its affiliates (hereinafter: “the
Observer”) subject to the Observer signing an undertaking towards the Company, which undertaking shall include non-disclosure obligations and an obligation to be bound by fiduciary duties similar to those set-forth in Article 254 of the
Israeli Companies Law – 1999 in the form to be agreed by the Purchaser and the Company. The Observer will be entitled to receive notices convening meetings of the Board, participate at such meetings and receive a copy of all minutes, written
resolutions, information, documents and any other material that will be remitted to the Board by the Company. The Observer will have no voting rights on the Company’s Board of Directors. 

 

	 	8.4	Save with the Company’s written approval, the Purchaser’s rights according to this Section 8 may not be assigned or transferred.

  

	9.	Miscellaneous 

  

	 	9.1	The parties will effect all the acts and sign all the documents that will be reasonably required in order to accomplish and fully effectuate the provisions of this
Agreement and the intention of the parties that are reflected by the contents thereof. 

  

	 	9.2	This Agreement, including the appendices thereto, contains and expresses all the terms and conditions agreed between the parties with respect to the subject matter
hereof. Any assurances, guarantees, written or verbal agreements, undertakings or representations regarding the subject matter of this Agreement, including memoranda of understanding, that have been given or made by the parties between them, but
prior to the making of this Agreement, and which have not been expressly stated in this Agreement, will not add to nor derogate from the undertakings and rights prescribed in this Agreement or resulting therefrom, and the parties will not be bound
thereby from the date of the signature of this Agreement onwards. 

  

	 	9.3	No waiver, extension, concession or forbearance from exercising any right under this Agreement will be of any effect unless made by express document signed by the
waiving party, and if made will only apply with respect to the specific instance mentioned in the document and will not derogate from any other rights of any of the parties under this Agreement. This Agreement may be amended only by a written
agreement executed by both parties. 

  

	 	9.4	None of the parties may assign or convey any undertaking or right which it has under this Agreement without the prior consent of the other party.

  

	 	9.5	 Notices under this Agreement will be conveyed in writing to the addresses of the parties appearing at the preamble of this Agreement and to the email
addresses detailed hereunder. Any notice sent by either of the parties to the other by 

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -12-

	 	
registered mail will be deemed to have been received after four business days from the date of posting. Notice sent by fax or emailed will be deemed to have been received on the same business day
on which it was sent (subject to despatch confirmation being furnished). Notice given by personal service will be deemed to have been received on the date of service. Purchaser’s fax number and email address: (314)-694-2594,
nancy.m.avioli@monsanto.com Company’s fax number and email address: +972-8-946-6724, haviv@evogene.com 

  

	 	9.6	In case any provision of the Agreement shall be held invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not
in any way be affected or impaired thereby. The parties hereto shall be obliged to draw up an arrangement in accordance with the meaning and the object of the invalid provision. 

Other than as to matters governed by Israeli corporate or securities laws, which shall apply in such cases, this Agreement, including all
Appendices hereto, shall be governed exclusively by, and construed solely in accordance with, the laws of the State of New York, without regard to the conflict of laws provisions thereof. All disputes arising under this Agreement or in connection
with the transactions hereunder shall be resolved exclusively in the competent court in the district of Tel-Aviv, Israel. 

remainder of page left blank intentionally 

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -13-

 In witness whereof the parties have set their hands on the date first above written:

  

					
	 /s/ Ofer Haviv
	 		 	 /s/ Stephen R. Padgette

	Evogene Ltd.	 		 	Monsanto Company

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -14-

 Exhibit 3.6.4 

Capitalization Tables 
 Capitalization Table August 27, 2008 
  

					
	 Shares
	  	 	20,808,568	  
	 Options
	  	 	4,027,187	  
	 Warrant - Service Providers
	  	 	133,545	  
	 Warrant - Investors
	  	 	226,824	  
		  	  
	  
	 
		  	 	25,196,124	  
		
	 Options - Series 1
	  	 	3,900,000	  
	 Options - Series 2
	  	 	4,551,584	  
		  	  
	  
	 
		  	 	8,451,584	  
		  	  
	  
	 
	 Total
	  	 	33,647,708	  
		  	  
	  
	 

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -15-

 Exhibit 3.11 

Claims Asserting Infringement of third parties IP Rights 
 Two claims letters from Genetic Technologies Limited (“GTG”), dated January 5, 2004 and March 9, 2004, claiming that the Company infringes GTG’s patent rights, and demanding the
Company to purchase licenses for the use of such patents, as further detailed in said letters. 

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -16-

 Exhibit 4.8 - Required Information 

 

			
	Purchaser’s Full Name	 	
	Purchaser’s Identity Number or a different Identification Number & type of number provided	 	
	Purchaser’s Country of Incorporation	 	
	Purchaser’s Complete Address	 	
	All information regarding the controlling shareholder, directly or indirectly, of the Purchaser (including name of such controlling shareholder and its holdings in the
Purchaser)	 	
	Information relating to agreements, whether written or oral, with regard to the purchase and/or holdings of Evogene’s securities or with regard to the voting rights
therein & stating the main points thereof	 	

 If a director is appointed to the Board of Directors of Evogene Ltd., the following additional information will be
required with regard to such director: 
  

			
	Full Name	 	
	ID number (if not a resident of Israel – passport number & country of issuance)	 	
	Date of Birth	 	
	Address for service of court papers	 	
	Nationality	 	
	If the director is an employee of an affiliate of Evogene or of a Principal Shareholder of Evogene – the position or positions that the director holds	 	
	The director’s education and occupation in the last five years, including information regarding the corporations in which the director serves as director, information regarding
the director’s education stating subjects and/or branches, the academic degree or diploma the director holds and the institutes in which they were acquired	 	
	Whether the director is a relative of a Principal Shareholder of Evogene	 	
	Whether the director holds securities of an affiliate of Evogene and details on such securities held	 	

 A “Principal Shareholder” – 

 

	(a)	 (a) A person or entity who/that holds 5% or more of the issued share capital of the Company or the voting power therein, (b) a person or entity
who/that is entitled to appoint one or more of the directors of the Company or its general manager, (c) a person or entity who/that holds office as a director of the Company or as its general manager, or

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -17-

	 	
(d) a corporation in which a person as aforesaid holds 25% or more of its issued share capital or of the voting rights therein or is entitled to appoint 25% or more of its directors. For the
purpose of the above: (a) the manager of a joint investment trust fund shall be deemed the holder of the securities included in the fund assets; (b) if a person holds securities through a trustee, the trustee shall also be regarded as
holder of the said securities. For this purpose, “trustee” – excluding a registration company and excluding someone who holds securities merely by virtue of his office as trustee for a settlement under section 46(a)(2)(f) the
Securities Law or as a trustee for an issue of shares to employees, as defined in section 102 of the Israel Income Tax Ordinance; 

  

	(b)	A subsidiary of the Company. 

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -18-

 Exhibit 6.3 

 

	To:	The Research Committee 

 The
Office of the Chief Scientist 
 Jerusalem 
 Relating to projects that have been financed by or are currently being financed by the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor (the “OCS”) and to
projects of the Company (as this term is defined below) that may be financed by the OCS in the future (the “Projects”). 

Undertaking 
 We, the undersigned, of
Monsanto Company, a company incorporated, organized and existing under the laws of Delaware and whose headquarters is at 800 N. Lindbergh Blvd., St. Louis, Missouri 63167 (“Monsanto”), having, by an agreement dated
August 27, 2008, committed to invest in Evogene Ltd. (the “Company”), in exchange for 3,272,727 Ordinary Shares of the Company; 
 Recognizing that the Company’s research and development Projects are currently, have been or will be financially supported by the Government of the State of Israel, through the OCS under and subject
to the provisions of The Encouragement of Research and Development in Industry Law 5744-1984 (the “R&D Law”) and the regulations, rules and procedures promulgated there under; 

Recognizing that the R&D Law places strict constraints on the transfer of know-how and/or production rights, making all such transfers subject to the
absolute discretion of the OCS’ research committee (the “Research Committee”), acting in accordance with the aims of the R&D Law and requiring that any such transfer receive the prior written approval of the Research
Committee; 

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -19-

 Hereby declare and undertake: 

 

	1.	To observe strictly all the requirements of the R&D Law and the regulations, rules and procedures promulgated there under, as applied to the Company and as directed
by the Research Committee, in particular those requirements stipulated under Sections 19, 19A and 19B of the R&D Law relating to the prohibitions on the transfer of know-how and/or production rights. 

 

	2.	As a shareholder of the Company, to make all reasonable efforts that the Company shall observe strictly all the requirements of the R&D Law and the regulations,
rules and procedures promulgated there under, as applied to the Company and as directed by the Research Committee, in particular those requirements stipulated under Sections 19, 19A and 19B of the R&D Law relating to the prohibitions on the
transfer of know-how and/or production rights. 

  

									
	 08/27/08
	 		 	 /s/ Stephen R. Padgette

	Date	 		 		 	Monsanto Company
		 		 		 	By:	 	 Stephen R. Padgette

		 		 		 	Title:	 	 VP, Biotechnology

  

	***	Confidential treatment has been requested for redacted portions of this exhibit. This copy omits the information subject to the confidentiality request. Omissions are
designated as [***]. A complete version of this exhibit has been provided separately to the Securities and Exchange Commission. 

  
 -20-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]